Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
A business making money today isn’t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. That said, here are two profitable companies that leverage their financial strength to beat the competition and one that may face some trouble.
One Stock to Sell:
Primoris (PRIM)
Trailing 12-Month GAAP Operating Margin: 2.9%
Listed on the NASDAQ in 2008, Primoris (NYSE:PRIM) builds, maintains, and upgrades infrastructure in the utility, energy, and civil construction industries.
Why Does PRIM Fall Short?
- Gross margin of 10.3% reflects its high production costs
- Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term
- Ability to fund investments or reward shareholders with increased buybacks or dividends is restricted by its weak free cash flow margin of 2.2% for the last five years
Primoris is trading at $83.08 per share, or 21.2x forward P/E. To fully understand why you should be careful with PRIM, check out our full research report (it’s free).
Two Stocks to Watch:
BrightSpring Health Services (BTSG)
Trailing 12-Month GAAP Operating Margin: 3.1%
Founded in 1974, BrightSpring Health Services (NASDAQ:BTSG) offers home health care, hospice, neuro-rehabilitation, and pharmacy services.
Why Could BTSG Be a Winner?
- Impressive 23.9% annual revenue growth over the last two years indicates it’s winning market share this cycle
- Revenue base of $14.37 billion gives it economies of scale and some negotiating power
- Sales outlook for the upcoming 12 months implies the business will stay on its desirable two-year growth trajectory
BrightSpring Health Services’s stock price of $60.45 implies a valuation ratio of 30.5x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Pfizer (PFE)
Trailing 12-Month GAAP Operating Margin: 29.6%
With roots dating back to 1849 when two German immigrants opened a fine chemicals business in Brooklyn, Pfizer (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a wide range of diseases and conditions.
Why Do We Like PFE?
- Massive revenue base of $63.7 billion in a highly regulated sector makes the company difficult to replace, giving it meaningful negotiating power
- Adjusted operating margin expanded by 18.5 percentage points over the last two years as it scaled and became more efficient
- Industry-leading 17.5% return on capital demonstrates management’s skill in finding high-return investments
At $26.86 per share, Pfizer trades at 9.7x forward P/E. Is now the time to initiate a position? See for yourself in our in-depth research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.